Jose Fernando Moura, PhD· @FernandoOnco · X·· 2 天前评分70
正文 · 原文
NATALEE: We’re talking about saving lives!
For the first time, the 6-year update shows an overall survival benefit with adjuvant ribociclib in HR+/HER2− early breast cancer.
Is this the practice-changing evidence we’ve been waiting for?
#ESMO26 @myESMO
166 浏览 · 2 赞 · 2 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Jose Fernando Moura, PhD · x.com